Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 22, 2025 10:00 ET | Source: SNS Insider pvt ltd

Anal Cancer Market Size to Reach USD 2.08 Billion by 2032, Fueled by Rising HPV-Linked Cases and Advancements in Targeted Therapies – SNS Insider

Austin, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Anal Cancer Market Size & Growth Analysis: According to SNS Insider, the Anal Cancer Market size was valued at USD 1.06 billion in 2024 and is...
February 03, 2025 16:05 ET | Source: Immuneering Corporation

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
December 17, 2024 08:00 ET | Source: Immuneering Corporation

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
December 10, 2024 08:00 ET | Source: Leapfrog Bio

Leapfrog Bio Presents Novel Genetic Sensitizing Mutation Linked to BET Inhibitors and Clinical Development Plans for Lead Product Candidate at the AACR Special Conference in Cancer Research

Leapfrog Bio announced AACR presentation describing the discovery, characterization, and clinical development plan for lead drug LFB-190.
October 15, 2024 08:00 ET | Source: Immuneering Corporation

Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer

Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
October 10, 2024 09:00 ET | Source: Targeted Oncology™

Targeted Oncology™ announces Eric Cheung, D.O., as the second recipient of the 2024 Oncology Icons award

CRANBURY, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Targeted Oncology™, a multimedia resource that offers engaging content and expert opinions on standard and emerging treatments in the field of...
August 06, 2024 16:05 ET | Source: Immuneering Corporation

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
July 31, 2024 16:05 ET | Source: Immuneering Corporation

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
May 07, 2024 16:05 ET | Source: Immuneering Corporation

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
May 06, 2024 16:30 ET | Source: Immuneering Corporation

Immuneering Recognizes Melanoma Awareness Month

Immuneering Recognizes Melanoma Awareness Month